DCC5189 |
Toldimfos Sodium |
Stimulator of metabolism, preventing diseases associated with parturition and peri-partum period, developmental and nutritional disorders in young animals, and bone growth disorders and tetany or paresis caused by calcium, magnesium, and phosphorus metabo |
|
DCC5190 |
Tonantzitlolone |
Natural agonist of TPRC1/4/5 channels, also acting as a dual PKCα and PKCθ activator, inducing an insulin resistant phenotype by inhibiting IRS1 and the PI3K/Akt pathway, activating the heat shock factor 1 (HSF1) transcription factor driving glucose depen |
|
DCC5191 |
Top1/tdp1-in-c12 |
Novel dual TOP1 and TDP1 inhibitor, inducing both cellular TOP1cc, TDP1cc formation and DNA damage, resulting in cancer cell apoptosis at a sub-micromolar concentration |
|
DCC5192 |
Top1210 |
Novel narrow spectrum kinase inhibitor, potently inhibiting P38a, Src, and Syk kinase activities |
|
DCC5193 |
Top-dnj |
Novel Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II, Exhibiting Antiflaviviral Activity |
|
DCC5194 |
Topki-nbd |
Novel highly specific fluorescent TOPK inhibitor |
|
DCC5195 |
To-pro3 Iodide |
Nucleic acid stain, acting on viable, early apoptotic and necrotic cells differentially, showing specific staining of nuclei without any staining of the cytoplasm |
|
DCC5196 |
Tortuosamine |
Natural psychoactive agent |
|
DCC5197 |
Tos-gly-pro-arg-anba-ipa |
Chromogenic peptide substrate for the rapid and specific photometric assay of recombinant hirudin (r-hirudin) |
|
DCC5198 |
Tosylaniline |
Selective CA IX inhibitor |
|
DCC5199 |
Toxt-in-8 |
Novel ToxT inhibitor, reducing Vibrio cholerae virulence in vivo and effectively inhibiting intestinal colonization in the infant mouse |
|
DCC5200 |
Tp-008 |
Novel probe for activin receptor-like kinase (ALK4 and ALK5) |
|
DCC5201 |
Tp-040 |
Novel inhibitor of O-GlcNAcase (OGA) |
|
DCC5202 |
Tp-238 Hydrochloride |
Novel probe for CECR2/BPTF bromodomains |
|
DCC5203 |
Tpe-gal |
First-in-class fluorescent drug delivery vesicle that can efficiently load both water-soluble and -insoluble anticancer drugs |
|
DCC5204 |
Tph1-in-23a |
Novel Peripheral Selective Tryptophan Hydroxylase 1 (TPH1) Inhibitor (IC 50 : 42nM) for Obesity and Fatty Liver Disease |
|
DCC5205 |
Tpi1609-10 |
Inhibitor of tyrosine recombinases and Holliday junction-resolving enzymes; Antibacterial |
|
DCC5206 |
Tpi-1917-49 |
Promising amyloid reducing agent by lowering the levels of Aβ. |
|
DCC5207 |
Tpi-2659-17 |
Novel Specific Inhibitor of Type I Collagen Production in Fibrosis |
|
DCC5208 |
Tpi-287 |
Novel taxane family member, reducing the brain metastatic colonization of breast cancer cells |
|
DCC5209 |
Tpl2-in-i |
Novel tumour progression locus 2 (Tpl2) kinase inhibitor |
|
DCC5210 |
Tpmp-i-2 |
Enhancer of the cytotoxic effect of immunotoxins (ITs) which results in increased apoptosis in different cancer cells |
|
DCC5211 |
Tpp-cl2 |
Mitochondria-activatable luciferin (MAL-Probe) |
|
DCC5212 |
Tp-s1-68 |
Novel Type-I Inhibitor of TIE-2 |
|
DCC5213 |
Tracizoline |
Potent I 2 -imidazoline receptor agonist |
|
DCC5214 |
Trans- Resveratrol-4’-sulfate Sodium Salt |
Metabolite of Resveratrol |
|
DCC5215 |
Trans-abcd |
Potent and selective NMDA agonist |
|
DCC5216 |
Trans-bopc1 |
Novel HuR binder, modulating HuR-RNA interactions |
|
DCC5217 |
Trans-cbtbp |
Novel KGA allosteric inhibitor |
|
DCC5218 |
Trans-miyabenol C |
Natural resveratrol trimer, acting as a protein kinase C inhibitor |
|